Nightstar Therapeutics plc (NASDAQ: NITE) is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.
View Top Employees from NIGHTSTAR THERAPEUTICS| Website | http://www.nightstartx.com |
| Ticker | NASDAQ:NITE |
| Revenue | $8.4 million |
| Funding | $160.8 million |
| Employees | 29 (4 on RocketReach) |
| Founded | 2013 |
| Phone | +44 20 7611 2077 |
| Fax | +44 20 7611 2032 |
| Technologies |
JavaScript,
HTML,
Google Analytics
+34 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Science and Engineering, Research, Healthcare, Genetics, Health Care, Health Diagnostics |
| Competitors | Iconic Therapeutics, Inc., Kodiak Sciences, ONL Therapeutics, SCYNEXIS, Inc. |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular NIGHTSTAR THERAPEUTICS employee's phone or email?
NIGHTSTAR THERAPEUTICS Questions
The NIGHTSTAR THERAPEUTICS annual revenue was $8.4 million in 2023.
Matthew Durning is the Co-Founder of NIGHTSTAR THERAPEUTICS.
4 people are employed at NIGHTSTAR THERAPEUTICS.
NIGHTSTAR THERAPEUTICS is based in London, Greater London.
The NAICS codes for NIGHTSTAR THERAPEUTICS are [325, 3254, 32].
The SIC codes for NIGHTSTAR THERAPEUTICS are [283, 28].
Top NIGHTSTAR THERAPEUTICS Employees
-
53
-
ViewViola Nabbanja
Clinical Trial Coordinator at NIGHTSTAR THERAPEUTICS
Croydon, England, United Kingdom1 -
ViewRoma Muccio
Senior Executive Administrator, Office of the Chief Executive Officer at NIGHTSTAR THERAPEUTICS
London, England, United Kingdom1
Related Companies
